TriangleNCT01210222 · OUTCOME
Progression-free Survival > 6 Months
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 90% Confidence Interval
- Time frame
- At 6 months
What was measured
Whether or not the patient survived progression-free for at least 6 months.
Analysis population: Eligible and treated patients
Groups in this outcome
Treatment (Trebananib)
Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Trebananib: Given IV
| Group | Source count |
|---|---|
| Treatment (Trebananib) | 32 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Trebananib) | 18.8 | Not reported | 8.5 | 33.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 8.5
- upper Limit
- 33.7
- value
- 18.8
- denoms
- counts
- group Id
- OG000
- value
- 32
- units
- Participants
- description
- Whether or not the patient survived progression-free for at least 6 months.
- dispersion Type
- 90% Confidence Interval
- groups
- description
- Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Trebananib: Given IV
- id
- OG000
- title
- Treatment (Trebananib)
- param Type
- NUMBER
- population Description
- Eligible and treated patients
- reporting Status
- POSTED
- time Frame
- At 6 months
- title
- Progression-free Survival > 6 Months
- type
- PRIMARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice